Southend Pharma Profile
Key Indicators
- Authorised Capital ₹ 7.50 M
as on 03-07-2024
- Paid Up Capital ₹ 4.99 M
as on 03-07-2024
- Company Age 35 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.40 Cr
as on 03-07-2024
- Revenue 9.63%
(FY 2023)
- Profit 37.17%
(FY 2023)
- Ebitda 5.92%
(FY 2023)
- Net Worth 15.52%
(FY 2023)
- Total Assets -4.10%
(FY 2023)
About Southend Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 7.50 M and a paid-up capital of Rs 4.99 M.
The company currently has active open charges totaling ₹1.40 Cr.
Saket Lohia, Sandhya Lohia, Ankit Lohia, and Six other members serve as directors at the Company.
- CIN/LLPIN
U51909WB1989PTC046785
- Company No.
046785
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Apr 1989
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Southend Pharma?
Board Members(9)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Megha Dhanuka  | Director | 03-Oct-2011 | Current |
| Saket Lohia | Director | 03-Dec-2018 | Current |
| Sandhya Lohia | Director | 14-Feb-2020 | Current |
| Ankit Lohia | Director | 03-Dec-2018 | Current |
| Jayant Dhanuka | Director | 02-Mar-2015 | Current |
| Radha Lohia | Director | 03-Oct-2011 | Current |
Financial Performance of Southend Pharma.
Southend Pharma Pvt Ltd, for the financial year ended 2023, experienced modest growth in revenue, with a 9.63% increase. The company also saw a substantial improvement in profitability, with a 37.17% increase in profit. The company's net worth Soared by an impressive increase of 15.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Southend Pharma?
In 2023, Southend Pharma had a promoter holding of 63.35% and a public holding of 36.65%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Evans Meditech Private LimitedActive 15 years 8 monthsSaket Lohia, Ankit Lohia and 3 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 06 Feb 2021 | ₹1.40 Cr | Open |
How Many Employees Work at Southend Pharma?
Unlock and access historical data on people associated with Southend Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Southend Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Southend Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
